Viridian Therapeutics, Inc.\DE (VRDN) Net Cash Flow (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Net Cash Flow of -$36.0 million for Q1 2026, down 316.81% year-over-year from $16.6 million in Q1 2025, and down 184.32% quarter-over-quarter from $42.7 million in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Net Cash Flow (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Net Cash Flow history runs 14 years deep, the most recent figure standing at -$36.0 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 316.81% year-over-year to -$36.0 million; the TTM figure through Mar 2026 stood at $60.1 million (up 144.69% YoY), while the FY2025 annual figure was $112.8 million, up 3588.65% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$36.0 million, down from $42.7 million in the prior quarter.
- The five-year high for Net Cash Flow was $312.9 million in Q3 2022, with the low at -$188.6 million in Q4 2022.
- The 5-year median for Net Cash Flow is $435000.0 (2022), against an average of $7.9 million.
- The sharpest annual moves came in 2022 and 2024: Net Cash Flow slumped 2032.6% in 2022, then soared 1218.35% in 2024.
- Viridian Therapeutics, Inc.\DE's Net Cash Flow stood at -$188.6 million in 2022, then jumped by 95.35% to -$8.8 million in 2023, then slumped by 1048.49% to -$100.7 million in 2024, then surged by 142.43% to $42.7 million in 2025, then tumbled by 184.32% to -$36.0 million in 2026.
- Business Quant data shows VRDN's Net Cash Flow at -$36.0 million in Q1 2026, $42.7 million in Q4 2025, and $52.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - | -11.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.36 Mn |
| Jun 30, 2026 | -11.36 Mn |
| Mar 31, 2026 | -36.04 Mn |
| Mar 31, 2026 | -36.04 Mn |
| Dec 31, 2025 | 42.74 Mn |
| Dec 31, 2025 | 42.74 Mn |
| Sep 30, 2025 | 52.32 Mn |
| Sep 30, 2025 | 52.32 Mn |
| Jun 30, 2025 | 1.11 Mn |
| Jun 30, 2025 | 1.11 Mn |
| Mar 31, 2025 | 16.62 Mn |
| Mar 31, 2025 | 16.62 Mn |
| Dec 31, 2024 | -100.72 Mn |
| Dec 31, 2024 | -100.72 Mn |
| Sep 30, 2024 | 92.65 Mn |
| Sep 30, 2024 | 92.65 Mn |
| Jun 30, 2024 | 16.03 Mn |
| Jun 30, 2024 | 16.03 Mn |
| Mar 31, 2024 | -11.19 Mn |
| Mar 31, 2024 | -11.19 Mn |